Therapy of melanoma patients harboring activating mutations in the BRAF (V-raf murine sarcoma viral oncogene homolog B1) oncogene with a combination of BRAF and MEK inhibitors is plagued by the development of drug resistance. Mutational events, as well as adaptive mechanisms, contribute to the development of drug resistance. In this context we uncover here the role of a miRNA, miR-579-3p. We first show that low expression of miR-579-3p is a negative prognostic factor correlating with poor survival. Expression levels of miR-579-3p decrease from nevi to stage III/IV melanoma samples and even further in cell lines resistant to BRAF/MEK inhibitors. Mechanistically, we demonstrate that miR-579-3p acts as an oncosuppressor by targeting the 3′UTR of two oncoproteins: BRAF and an E3 ubiquitin protein ligase, MDM2. Moreover miR-579-3p ectopic expression impairs the establishment of drug resistance in human melanoma cells. Finally, miR-579-3p is strongly down-regulated in matched tumor samples from patients before and after the development of resistance to targeted therapies.
Therapy of melanoma patients harboring activating mutations in the BRAF (V-raf murine sarcoma viral oncogene homolog B1) oncogene with a combination of BRAF and MEK inhibitors is plagued by the development of drug resistance. Mutational events, as well as adaptive mechanisms, contribute to the development of drug resistance.
In this context we uncover here the role of a miRNA, miR-579-3p. We first show that low expression of miR-579-3p is a negative prognostic factor correlating with poor survival. Expression levels of miR-579-3p decrease from nevi to stage III/IV melanoma samples and even further in cell lines resistant to BRAF/MEK inhibitors. Mechanistically, we demonstrate that miR-579-3p acts as an oncosuppressor by targeting the 3′UTR of two oncoproteins: BRAF and an E3 ubiquitin protein ligase, MDM2. Moreover miR-579-3p ectopic expression impairs the establishment of drug resistance in human melanoma cells. Finally, miR-579-3p is strongly down-regulated in matched tumor samples from patients before and after the development of resistance to targeted therapies.
miRNA | melanoma | targeted therapy | drug resistance M alignant melanoma is the most aggressive form of skin cancer. Mutational activation of the BRAF (V-raf murine sarcoma viral oncogene homolog B1) oncogene, which usually affects the Valine 600 codon, occurs in ∼50% of melanoma patients (1) . These mutations cause the constitutive activation of the BRAF kinase and, in turn, of the MAPK pathway, leading to uncontrolled cell proliferation (2) . Treatment options for melanoma patients bearing BRAF V600 mutations have drastically improved, thanks to the introduction of BRAF inhibitors (3) . Whereas most patients experience an initial response to treatment, relapse is common because of the development of acquired drug resistance, which limits the duration in time of therapy (4, 5) . Nevertheless, it is important to point out that about 10-15% of patients achieved long-term survival and are stable after more than 6 y of monotherapy with vemurafenib (6) .
The identification of core resistance pathways has become a major focus of research. Usually, BRAF-resistant cells show reactivation of the MAPK pathway and this has led to the clinical development of combination therapies directed to simultaneously target BRAF and MEK kinases to mitigate the emergence of resistance (7) (8) (9) . Despite recent results from the pooled analysis of the Combi -d and -v studies, which showed a 3-y overall survival rate of 38% and a positive outcome in patients with a favorable prognosis (normal LDH value, low tumor burden, and so forth), resistance still represents a problem for the majority of patients treated with targeted agents (10, 11) . A recent DNA deep-sequencing analysis of 100 tumor samples from 44 patients whose melanomas developed acquired resistance confirmed that mutations in the MAPK pathway are found in the majority of cases (70%), mostly related to RAS mutations, mutant BRAF amplifications, and alternative splice variants (12) . PI3K-PTEN-AKT-up-regulating genetic alterations were evident in 22% of progressive melanomas (12) . Furthermore, molecular lesions in both core drug escape pathways were detected concurrently in 18% of cases (12) . However, in the remaining 26% of samples analyzed, no new mutation could be detected, which suggests the involvement of epigenetic or posttranscriptional changes at the basis of resistance in a significant proportion of cases.
It is generally accepted that melanoma cells exposed to kinase inhibitors undergo adaptive epigenetic changes, which activate key survival pathways that help the emergence of drugresistant cells. These responses mostly occur within hours of drug treatments and are characterized by a reversible condition because drug removal resets the compensatory signal to its basal state (13) . Moreover, early adaptive responses limit the initial efficacy, leading to incomplete responses and favor the selection of a subpopulation of resistant clones, which ultimately cause disease progression (14, 15) . We and others, for example, have demonstrated that the ErbB3 receptor is a key player in the development of resistance to therapies in melanoma (16, 17) . This receptor is involved in the activation of an early feedback survival loop upon melanoma cell exposure to BRAF and MEK inhibitors, and monoclonal antibodies directed against ErbB3 act synergistically in combination with BRAF and MEK inhibitors to impair the development of drug resistance (16, 18) . In this paper, to investigate the possible role of the epigenetic or posttranscriptional changes in the establishment of drug resistance, we demonstrate that miRNAs could be novel and important effectors. MicroRNAs (miRNAs) are small noncoding RNAs that modulate gene expression by mRNA silencing or degradation, which usually have pleiotropic
Significance
In this paper we identify a previously poorly characterized miRNA, namely miR-579-3p, as a master regulator of melanoma progression and drug resistance. Our results underscore the complexity of adaptive mechanisms that help the establishment of resistance to target therapies and the necessity to identify them to develop more effective combination therapies.
effects because of their ability to target simultaneously multiple mRNAs (19) . Changes in miRNAs expression levels are known to play a key-role in various human cancers (20, 21) , including melanoma (22) . Gene-expression profiling studies previously showed that a network of miRNAs is controlled by BRAF/MEK/ ERK signaling (23) . In this paper we identify a mechanism of drug resistance in BRAF mutated melanoma centered around a poorly characterized miRNA, miR-579-3p.
Results miR-579-3p Targets the 3′UTR of BRAF Oncogene and Is DownRegulated in Vemurafenib-Resistant Melanoma Cells. To investigate the role of miRNA in the establishment of resistance to BRAF and MEK inhibitors in melanoma, we first performed a bioinformatic analysis using the online algorithm miRò, which integrates data from various online sources, such as databases of miRNAs, ontologies, diseases, and predicted or validated targets into a unified database (24) . This tool allowed us to predict some miRNAs to play a role in BRAF mutated melanoma progression: miR-1206 (MIMAT0005870), miR-496 (MIMAT0002818), miR-9-5p (MIMAT0000441), and miR-579-3p (MIMAT0003244) ( Table  S1 ). Among these miRNAs, miR-579-3p was a potentially promising candidate because it was found to be down-regulated during melanoma progression with a statistically significant correlation (P < 0.05) (Table S1 ). miR-579-3p has two seed regions that match the 3′UTR of human BRAF (NM_004333.4). These two seed regions, based on TargetScan and microrna.org predictions, are nucleotides 3-9 and 47-53 (Fig. 1A) . To verify these predictions, the BRAF 3′UTR containing the two miR-579-3p binding sites was cloned downstream of the luciferase ORF. This reporter construct was used to transfect HEK-293 cells together with miR-579-3p. The introduction of miR-579-3p in HEK-293 cells with the BRAF wild-type 3′UTR construct led to a significant inhibition of luciferase activity compared with the negative control (Fig. 1B) . Mutagenesis of each of the two miR-579-3p binding sites within the BRAF 3′UTR was able to reduce the ability of miR-579-3p to impair luciferase expression (Fig. 1B) . In addition, deletion of both the 3′UTR binding sites (Braf Double mut) caused an almost complete rescue of luciferase expression in the presence of the cotransfected miRNA (Fig. 1B) . Next, we evaluated whether miR-579-3p activity on the BRAF 3′UTR was evident also in BRAF-mutated human melanoma cells. For this reason we transiently transfected a miR-579-3p mimic or a scrambled control (Scr) in WM266 and the M14 cells, carrying V600D and V600E BRAF mutations, respectively. Overexpression of miR-579-3p in both cell lines strongly reduced endogenous BRAF expression at the protein and mRNA levels compared with the control ( (Fig. S1 ). Finally, we decided to measure miR-579-3p expression in three BRAF mutated melanoma cell lines resistant to vemurafenib recently derived in our laboratory (18) . miR-579-3p expression was strongly down-regulated in resistant M14, A375 (both BRAF V600E), and WM266 (BRAF V600D) compared with wild-type cells (Fig. 1E) . Moreover, because BRAF overexpression has been detected in a significant percentage of patients who developed resistance to BRAF inhibitors (14) , we decided to assess BRAF expression levels in our resistant melanoma cells. Indeed, we found BRAF to be overexpressed in M14R, WM266R, and A375 cells (Fig. 1F) . These data led us to conclude that miR-579-3p controls BRAF expression and that RNA levels of miR-579-3p and BRAF are inversely correlated in resistant cells.
High miR-579-3p Levels Correlate with Good Prognosis in Melanoma
Patients. Mutated oncogenic BRAF is fundamental for melanoma maintenance (25) . Because we have shown above that this kinase is a molecular target of miR-579-3p, we postulated that there could be a correlation between these two molecules in melanoma prognosis. To test our hypothesis, we used the Gene Expression Omnibus (GEO) Dataset (accession no. GSE59334) to query the prognostic value of miR-579-3p expression levels in 73 melanoma patients in association with BRAF mutational status. The dataset was interrogated with the online algorithm, MIRUMIR, a tool able to assess whether a specific miRNA of interest is able to predict patient survival, represented by Kaplan-Meier plots. For each dataset, which corresponds to various cancer types, samples are split in two groups: high or low microRNA expression levels (26, 27) . As shown in the Kaplan-Meier plot in Fig. 2A , patients with high miR-579-3p expression (n = 33) were found to have a better survival probability than low miR-579-3p expressors (n = 40) (P = 0.037).
Next we decided to investigate, through qRT-PCR, the expression of miR-579-3p in human samples and we used formalin-fixed paraffin embedded (FFPE) samples for these analysis (28, 29) . We tested 10 samples from melanocytic nevi, 4 samples from dysplastic nevi, 10 samples from stage I/II melanomas, and 9 samples from stage III/IV melanomas. The results (Fig. 2B) show that miR-579-3p is down-regulated in melanoma patients compared with melanocytic and dysplastic nevi. Of note, miR-579-3p reduction is higher and statistically significant in stage III/IV melanomas than stage I/II melanomas, in line with the existence of an inverse correlation between miR expression and clinical outcome. Finally, to confirm our previous evaluations, we decided to test through qRT-PCR miR-579-3p expression in primary normal human epidermal melanocytes and in eight BRAF mutated melanoma cell lines (M14, LOX IMVI, COLO 38, MALME-3M, M229, SKMEL5 BRAF V600E, WM266, and WM115 V600D). As expected, our results show that miR-579-3p is significantly down-regulated in all malignant melanoma cell lines tested compared with normal melanocytes (Fig. 2C ).
miR-579-3p Expression Controls Growth and Migration of Human
Melanoma Cells. In melanoma cells mutant BRAF in position V600 constitutively activates ERK1/2, which in turn stimulates the MAPK pathway (30) . Because miR-579-3p is able to strongly reduce the endogenous BRAF expression levels, we decided to investigate the biological effect of miR-579-3p overexpression after transient transfection. When Western blot analysis was performed with protein extracts of WM266, M14, LOX IMVI, and WM115 cells transfected with miR-579-3p, we were able to observe a strong reduction of ERK1/2 phosphorylation (Fig. 3A ). Next we decided to evaluate the effect of miR-579-3p overexpression on cell viability and migration. MTT ([3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] tetrazolium reduction assay) assays ( Fig. 3B) showed that miR-579-3p forced expression was able to impair melanoma cell viability compared with scrambled miRNA. Of note, we used as control a specific BRAF siRNA, which was able, as expected, to inhibit melanoma cell growth to the same extent as miR-579-3p transfection (Fig. 3F ). To confirm these data, we carried out in vitro colony formation assays. Representative pictures and their quantification confirm that miR-579-3p was able to strongly affect melanoma cell growth (Fig. 3C ). Conversely, when we silenced miR-579-3p endogenous levels with a specific anti-miR, we observed an increase of WM266 melanoma cell growth (Fig. 3D ). Finally, we investigated whether BRAF-signaling inhibition through miR-579-3p overexpression could also affect melanoma cell migration. miR-579-3p was able to strongly affect melanoma cell migration in a transwell chamber assay in response to FBS-stimuli (Fig. 3E ). These data on cellular migration were confirmed by "scratch" assays ( Fig. S2 ).
miR-579-3p Induces Melanoma Cell Apoptosis and Inhibits Cell Cycle
Progression. To provide further insight into the biological effect of miR-579-3p, we evaluated apoptosis induction by flow cytometry in WM266, M14, LOX IMVI, and WM115 melanoma cells. Consistent with our previous findings, we observed that miR transient transfection was able to induce a strong level of apoptosis 48 h after transfection (Fig. 4A ). These data led us to measure the level of expression of some effectors of apoptosis and cell cycle progression in human melanoma cells upon miR-579-3p transfection. miR-579-3p was able to induce a strong increase of p53 protein levels and also a slight but evident induction of its phosphorylation, consistent with the strong activation of apoptosis (31) (Fig. 4B ). Importantly, we were able also to observe a strong upregulation of p21, which is transcriptionally activated by p53 (32); in contrast no change in the expression levels of p27 was detected. We confirmed these results by evaluating the activation status of Caspases 3/7 (33). We were able to observe, as expected, a strong activation of these effectors in miR-579-3p transfected melanoma cells (Fig. 4C ). To better assess the effect of miR-579-3p forced expression on cell cycle progression, we performed FACS analysis on WM266 melanoma cells. miR transfection strongly inhibited cell cycle progression through an increase of G0/G1 (Fig. 4D ), in accord with the strong activation of p21, which has been widely described as a mediator of p53-dependent G1 growth arrest (31, 32) . Finally, because p21 is a negative regulator of cell cycle progression by inducing G0/G1 block (32), we tested its role in miR-579-3p-induced cell cycle arrest. To this purpose we used a specific siRNA to knockdown p21 expression in miR-579-3p-transfected cells. Cell cycle analysis clearly indicated that p21 knockdown resulted in a partial rescue of cell cycle progression, thus compensating for Fig. 2 . High miR-579-3p expression correlates with good prognosis in melanoma patients. (A) Kaplan-Meier survival curves for miR-579-3p expression in melanoma patients in association with BRAF mutational status were obtained through the GEO dataset (accession no. GSE59334) from the online software MIRUMIR. The P-value of 0.037 was obtained from log-rank tests comparing the two Kaplan-Meier curves. (B) Box-whisker plots of miR-579-3p expression were determined from FFPE human samples (bold lanes represent median value). P < 0.05 vs. melanocytic nevi. (C) Total RNA of normal melanocyte and of eight melanoma cell lines was extracted and subjected to qRT-PCR. Error bars, ±SD, P < 0.05. miR-579-3p overexpression (Fig. 4E) . In contrast, cotransfection of a nontargeting siRNA (ContSi) did not affect cell cycle progression in the same conditions (Fig. 4E) . These results demonstrate that miR-579-3p acts as a tumor suppressor in BRAF mutated melanoma cells and that p21 is a major downstream mediator of G0/G1 block and apoptosis following miR-579-3p overexpression.
miR-579-3p Directly Targets the MDM2 Oncogene in Human Melanoma
Cells. Our previous results, together with the notion that a single miRNA is able to target multiple mRNAs (19) , led us to postulate that miR-579-3p could potentially target other important oncogenes involved in melanoma cell proliferation and survival. For these reasons we searched other potential targets of miR-579-3p using some bioinformatics algorithms. DIANA Lab and miRanda algorithms identified, as a potential target of miR-579-3p, one of the most relevant human proto-oncogenes: the E3 ubiquitin protein ligase MDM2 (NM_002392.5) (34) . MDM2 has two seed regions for this miRNA on its 3′UTR: nucleotides 529-536 and 999-1008 (Fig. 5A ). These predictions were also very intriguing in light of the results shown in the previous section, where we observed that miR-579-3p forced expression increased p53 and p21 levels (Fig. 4B) . MDM2 is known not only to be the major negative regulator of p53, because it is an E3 ubiquitin ligase that can drive its poly-ubiquitination and degradation (34) , but also to be a negative regulator of p21 (35) . Moreover, MDM2 is expressed at high levels in metastatic melanoma (36) . To verify our hypothesis, MDM2 3′UTR, containing the two miR-579-3p binding sites, was cloned and transfected as described above. The results show that miR-579-3p induced a significant inhibition of luciferase activity compared with the negative control (Fig. 5B) . In addition, mutagenesis of each of the two miR-579-3p binding sites within the MDM2 3′UTR reduced the ability of the miR to affect luciferase expression (Fig. 5B) . When we deleted both binding sites (MDM2 Double mut) we also obtained a stronger degree of rescue of luciferase expression (Fig. 5B) . Moreover, we decided to evaluate the effect of miR-579-3p on endogenous MDM2 expression as described above. The results in Fig. 5 C and D demonstrate that miR-579-3p overexpression specifically reduced endogenous MDM2 at both protein and mRNA levels compared with the control. Increased expression of miR-579-3p in transfected cells was confirmed by qRT-PCR (Fig. 5 C and D, Right) . Finally, because we have previously shown that miR-579-3p is down-regulated in a panel of melanoma cell lines (Fig. 2C) , we evaluated MDM2 expression in the same cells and in normal human epidermal melanocytes, as control. As expected, MDM2 was found to be overexpressed in all malignant melanoma cell lines tested compared with normal melanocytes (Fig. S3) .
miR-579-3p Potentiates Melanoma Cell Growth Inhibition Induced by
BRAFi and MEKi. In the light of our findings that miR-579-3p is able to strongly impair melanoma cell growth and apoptosis, we decided to investigate the effect of miR-579-3p overexpression in combination with BRAF inhibitor (BRAFi) and MEKi. First, we transiently transfected miR-579-3p or scrambled miRNA for 72 h in the presence of the BRAF inhibitor vemurafenib. The results of MTT assays clearly showed that miR-enforced expression in WM266 cells was able to strongly potentiate vemurafenib inhibition on melanoma cell growth compared with control (Scr) (Fig. 6A) . The same results were obtained in M14 melanoma cells (Fig. 6D) . To confirm these data, we carried out in vitro colony formation assays in which WM266 cells were transfected with miR-579-3p or the negative control for 7 d in the presence of vemurafenib. Results shown in Fig. 6B confirmed the strong inhibition of melanoma cell growth induced by miR-579-3p in association with vemurafenib. Conversely, anti-miR-579-3p strongly reduced drug-induced inhibition of melanoma cell growth (Fig. 6C and  Fig. S4 ). Moreover, to provide further insight into the biological effect of miR-579-3p/vemurafenib combination, we evaluated apoptosis induction in WM266 and M14 cells. The results in Fig. S5 show that miR overexpression potentiated apoptosis induced by vemurafenib. We also assessed whether miR-579-3p expression can potentiate the efficacy of the BRAFi + MEKi combination. First, we transiently transfected miR-579-3p or scrambled miRNA for 72 h in the presence of the BRAF inhibitor vemurafenib and the MEK inhibitor trametinib. miR overexpression potentiated the small molecules inhibitory effect on WM266 and M14 cell growth (Fig. 6 E and F) . Moreover, we confirmed these data through the long-term in vitro colony formation assay, performed as described above (Fig. S4, Center) . The MAPK pathway is capable to strongly activate the transcription factor AP1, composed of dimeric association of Jun and Fos proteins (37) , which is known to play an important role in melanoma progression (38) . Therefore, we investigated the ability of miR-579-3p to affect AP1 activity. To test this hypothesis, we cotransfected WM266 and M14 cells with a Pgl3 basic construct carrying the AP1 responsive elements, cloned upstream of the firefly luciferase coding region, together with miR-579-3p. The results (Fig. S6) show a reduction of the AP1-luciferase vector activity by miR-579-3p. When we combined vemurafenib with miR overexpression, we observed a further reduction of the AP1 luciferase expression (Fig. S6) . 
miR-579-3p Expression both Impairs the Establishment of Drug
Resistance and Reverts Drug Resistance. Based on the previous findings, we decided to investigate whether miR-579-3p may affect the development of drug resistance and sensitize resistant cells to drug treatment using two different assays. In the first case, using in vitro colony formation assays, we tested the consequence of forced miR-579-3p expression in BRAF-sensitive melanoma cells exposed chronically to vemurafenib for 28 d. Our data, shown in Fig. 6G , demonstrated that melanoma cells where miR-579-3p was overexpressed completely lost the ability to form vemurafenib-resistant colonies. In contrast, control miRNA-transfected cells were only initially affected by exposure to vemurafenib (after 7 d of drug exposure), but at later times succeeded in the establishment of resistant colonies (Fig. 6G) . Using a second approach, we determined whether miR-579-3p expression was able to impair the growth of vemurafenib-resistant melanoma cells in combination with the MEKi trametinib. Indeed, miR overexpression strongly potentiated trametinib inhibition of vemurafenib-resistant melanoma cell growth compared with Scr-transfected cells (Fig. 6H) .
miR-579-3p Is Down-Regulated in Melanoma Patients Who Developed
Resistance to Target Therapies. We next asked whether miR-579-3p down-regulation observed in vemurafenib-resistant melanoma cells selected in vitro is also occurring in melanoma patients in the clinic.
To answer this question, we isolated total RNA from FFPE tumor samples before kinase inhibitor treatment or from metastatic lesions after relapse from four patients who developed resistance to BRAF inhibitors. Data, shown in Fig. 7A , clearly demonstrate that miR-579-3p was strongly down-regulated in all posttherapy melanoma samples tested. In particular in patients #3 and #4 the presence of miR-579-3p was only barely detectable in posttreatment samples. To confirm our previous evaluations and to underscore the possible inverse correlation between miR-579-3p down-regulation and its targets overexpression, we performed qRT-PCR to evaluate BRAF and MDM2 mRNA levels on the same samples. Indeed we observed that BRAF mRNA was overexpressed in all melanoma patients at various levels, with the highest expression in patient #3, thus demonstrating a strong correlation between miR-579-3p downregulation and BRAF overexpression (Fig. 7A) . Finally, we assessed MDM2 levels and found, as also expected in this case, its overexpression in three of four patients tested after treatments. These data, in line with our previous evaluations, not only confirmed the importance of BRAF alterations as possible core escaping pathways in melanoma drug resistance (11, 39, 40) , but also offer new insight on the relevance of MDM2 overexpression in patients who developed resistance to target therapies. To confirm our hypothesis, which attributes a novel role in melanoma resistance to the deregulation of miR-579-3p/MDM2 axis, we queried the GEO dataset (accession no. GSE50509), which includes the expression profiling data relative to 30 patients, whose melanomas developed resistance to vemurafenib or dabrafenib. This finding confirmed that MDM2 is overexpressed (2.8-fold), whereas miR-579-3p is down-regulated (0.38-fold) compared with the RNA of the same patients before commencing treatments (significance levels >1.5 and <0.5).
Discussion BRAF and MEK inhibitors have become leading weapons in the battle against melanoma, with activating mutations in the BRAF oncogene (7-9). However, this combination therapy is still plagued by the development of acquired resistance, which in most cases leads to an intractable condition. Hence, it is necessary to identify additional mechanisms responsible for the establishment of drug resistance. Adaptive mechanisms of resistance have been discovered that do not involve gene mutations but instead a dynamic reprogramming of intracellular pathways. In this context, we searched for the potential involvement of microRNAs because they are key members of the regulatory machinery of eukaryotic cells, both in normal and pathological conditions (21) . It is well established that miRNAs are central to the determination of cellular identity, function, and adaptation to environmental changes. Significance Analysis of Microarrays performed on melanomas and normal melanocytes recently resulted in the identification of 32 differentially expressed miRNAs (41) . Moreover a highly sensitive microarray profiling showed that a network of 420 miRNAs is controlled by B-Raf/MEK/ERK signaling (23) . More recently, detailed investigations of individual microRNAs have demonstrated the involvement of miR-125b, miR-365, and miR-425 as tumor suppressors in metastatic melanoma, and of miR-3151 as oncomiR (refs. 42-44, respectively). However, none of the previous studies has directly asked whether miRNAs may play a role in the development of drug resistance, in particular in the context of target therapies with kinase inhibitors. In this paper we provide strong evidence that a previously poorly characterized miRNA, miR-579-3p, acts not only as an oncosuppressor whose downregulation is linked to the progression of metastatic melanoma, but also as a factor contributing to the development of drug resistance. In the first instance we show that low tumor-expression levels of this miRNA are associated with poor survival of melanoma patients and that there is a gradual decrease of its expression during disease progression, from the highest levels in normal nevi, to intermediate levels in stage I/II disease, to low levels in stage III/IV disease. This evidence is strengthened by in vitro studies, where we showed that miR-579-3p overexpression was able to reduce melanoma cell growth both individually and in combination with kinase inhibitors. However, the most interesting observation is the link between miR-579-3p and drug resistance. Indeed, both upon selection of drug resistant cells in vitro and in tumor samples from relapsed patients after therapy with kinase inhibitors miR-579-3p levels underwent a further down-regulation compared with drug sensitive cells or tumors, respectively. The link with drug resistance was further validated in a set of in vitro clonogenic assays, which proved how miR-579-3p-enforced expression was able to both revert drug resistance to a BRAF inhibitor in combination with a MEK inhibitor and, more importantly, to avoid the establishment of acquired drug resistance. The other relevant finding of the present work is that miR-579-3p was able to simultaneously affect two pathways required for BRAF mutated melanomas to proliferate, namely the BRAF/MAPK and MDM2/p53 pathways. Although we cannot rule out the possibility that this miRNA down-regulates additional targets in melanoma cells, we believe that its potency in the induction of cell growth arrest and apoptosis has to be attributed to its interference with these two complementary pathways. Taken together, these results allow us to draw the model depicted in Fig. 7B . In normal melanocytes (Fig. 7B, Left) , high endogenous miR-579-3p levels keep under check the expression of both BRAF and MDM2, and by doing so strongly control cell proliferation. Upon acquisition of BRAF activating mutations and melanoma progression (Fig. 7B,  Center) , miR-579-3p levels decrease, and this facilitates further melanoma cell growth by partial loss of this feedback negative regulatory circuit, which ends up in increase of BRAF as well MDM2 protein levels. Finally, in drug-resistant cells (Fig. 7B,  Right) , further reduction of miR-579-3p expression leads to complete loss of the negative feedback regulatory circuit leading to additional increases in BRAF and MDM2 levels, and uncontrolled cell growth, proliferation, and enhanced cell migration and metastasis. In this regard it will be important in the future to investigate in detail the mechanisms responsible for miR-579-3p expression and how these are affected during melanoma progression and development of drug resistance. miR-579-3p could be regulated by specific transcription factors, whose expression is altered during the development of drug resistance.
In this regard, a possible role could be played by the microphthalmia-associated transcription factor (MITF), a known master regulator of melanocyte development (45) . MITF's role in the establishment of resistance to targeted therapies in melanoma is The model of miR-579-3p expression during melanoma progression and in the establishment of resistance to target therapies. In normal melanocyte the levels of expression of miR-579-3p are high, thus resulting in the correct balance of cell proliferation, migration, and normal control of apoptosis through the inhibition of its target genes: BRAF and MDM2 (Left). In BRAF-mutated cells, the levels of miR-579-3p are lower and the expression levels of its target genes are higher thus causing enhancement of cell proliferation, migration, and inhibition of apoptosis (Center). Finally, in BRAFi-resistant melanoma cells the levels of miR-579-3p are minimal and its target gene has the highest levels of expression compared with the other models (Right); this condition contributes to the establishment of resistance to target therapy.
still controversial. Recent data strongly correlated loss of MITF expression with drug resistance (46) (47) (48) . miR-579-3p is an intronic miR located in intron 11 of the human gene ZFR (Zink-finger recombinase), and it is probably coexpressed with its host gene (49) . Interestingly, the ZFR gene is a putative target of MITF because its promoter has MITF consensus binding sites. Taken together, these observations lead to the hypothesis that downregulation of MITF-during the development of drug resistance is responsible for decreased expression of downstream miR-579. Our results, which identify miR-579-3p as an oncosuppressor miRNA and an antagonist of drug resistance, suggest that this miRNA could be considered as a potential therapeutic candidate in combination therapies. Inhibition of cell growth caused by miR-579-3p overexpression is moderate, as expected from the down-regulation of an oncogenic driver. Therefore, one might predict that chronic therapy would be necessary as monotherapy. However, we have shown that short-term overexpression of the miRNA, in combination with prolonged drug treatment, strongly impairs development of resistance. Another interesting aspect is the possibility to use miR-579-3p as a biomarker in the blood of melanoma patients for predicting response to therapy or development of drug resistance (50, 51) . miRNAs are very stable in plasma at different pH and temperature because they could be packaged in exosomes or associated with RNA-binding proteins, like Argonaute2 or lipoprotein complexes, which prevent their degradation (19, 51, 52) . Taken together, these observations may open up new avenues not only for the use of miRNAs to develop new combination therapies for melanoma, resulting in long-term disease control, but also to identify novel and promising biomarkers capable to predict the insurgence of resistance.
Methods
Bioinformatics Analyses. Bioinformatics analyses were performed using these specific programs: Targetscan (www.targetscan.org/), microrna.org (www.microrna.org/), miRò (microrna.osumc.edu/miro/), DIANA Lab (diana.imis. athena-innovation.gr/DianaTools/index.php), and MIRUMIR (www.chemoprofiling. org/cgi-bin/GEO/MIRUMIR/web_run_MIRUMIR.V1.pl) (26, 27) .
Cell Lines. Human melanoma cell lines M14, LOX IMVI, COLO 38, MALME-3M, and SKMEL5 (V600E) were obtained from the laboratory of F. Marincola, National Institutes of Health, Bethesda, MD; cell lines WM115, WM266 (V600D), and M229 (V600E) were obtained from the laboratory of T. Ribas, University of California, Los Angeles, CA. Resistant melanoma cells were selected as described in our previous work (20) . All human melanoma cell lines used in the present work were cultured in RPMI supplemented with 10% (vol/vol) FBS; HEK-293 cells were cultured in DMEM supplemented with 10% (vol/vol) FBS.
Antibodies, Western Blot Analysis, and Reagents. Antibodies against BRAF, MDM2, ERK 1/2, p21, p53, p27, and GAPDH were obtained from Santa Cruz Biotechnology. Phospho-ERK 1/2 and phosphor-p53 were purchased from Cell Signaling Technology. Antivinculin, anti-rabbit, and anti-mouse were purchased from AbCam. Western blot analyses were performed as described in our previous work (15, 20) . Vemurafenib and trametinib were obtained from Selleck Chemicals. TaqMan probes for BRAF, MDM2, GAPDH, miR-579-3p, and RNU48 were purchased from Applied Biosystems.
RNA Extraction and Real-Time PCR Analysis. RNA was extracted using TRIzol method (Invitrogen) and quantitated by spectrophotometry. Real-time PCR was assayed by TaqMan Gene Expression Assays (Applied Biosystems).
Clinical Data Analysis. Survival probabilities related to miR-579-3p expression levels in melanoma patients in association with BRAF mutational status were determined with the GEO dataset (accession no. GSE59334).
Tissue Samples. Total RNA was extracted from the FFPE samples from 10 melanocytic nevi, 4 dysplastic nevi, 10 stage I/II melanomas, 9 stage III/IV melanomas, and from 4 patients before and after BRAF inhibitor treatment, as described in the work by Ma et al. (29) . Real-time PCR was assayed as described above. The use of human samples was approved by Istituto Pascale's Ethical Committee with the protocol DSC/2893 on April 11, 2015. All patients signed a general informed consent, which allowed use of this material for research purposes and which was analyzed in an anonymous manner at the Istituto Nazionale per la Cura dei Tumori "Fondazione G. Pascale."
Luciferase Assays. To generate BRAF and MDM2 luciferase reporter constructs, the 3′UTR of each gene was cloned downstream of the luciferasecoding sequence in the psiCHECK-2 at the XchoI and NotI restriction sites (Promega). Mutations were introduced into the miRNA-binding sites by using the QuikChange Mutagenesis Kit (Stratagene). All of the transfection studies were performed with 500 ng of each plasmid.
Cell Proliferation Assay and in Vitro Colony Formation Assay. Viability of cells was examined with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Cell Titer 96 AQueous One Solution Cell Proliferation Assay (Promega), according to the manufacturer's protocol. The plates were analyzed in a Multilabel Counter (Bio-Rad Laboratories). Cells viability was also determined by Crystal violet staining, as described in our previous work (15, 20) .
Transwell Migration Assay. WM266 cells were transfected with miR-579-3p or with the Scr for 24 h, and then harvested by trypsinization and seeded upon 8-nm pore-size culture inserts (Transwell; Costar) placed into 24-well culture plates, separating the upper and the lower chambers. In the lower chamber, 400 mL of RPMI 10% (vol/vol) FBS was added. After 24 h of incubation, the migrating cells were stained with staining solution [0.5% Crystal violet in 30% (vol/vol) methanol]. Cells were then dissolved in a methanol/SDS solution and the adsorbance (595 nm) was read using a microplate ELISA reader.
FACS Analysis. Annexin V binding assay was performed to quantify apoptosis in cells transfected with miR-579-3p or with the Scr, and then treated or not with vemurafenib or trametinib for 48 h, as described in our previous work (20) . Cell cycle analysis, using a specific kit (Millipore), was performed in cells transfected as described above. Flow cytometric analysis to determine caspase 3/7 activity was performed according to the manufacturer's instructions (Millipore).
Statistical Analysis. Data from at least three separate experiments are presented as means ± SD. P values were calculated using Student's t test and significance level has been defined as P < 0.05. All experiments shown, except for the ones that involve clinical samples, were performed independently at least three times.
